Research programme: proinsulin-transferrin fusion protein - Ventria Bioscience

Drug Profile

Research programme: proinsulin-transferrin fusion protein - Ventria Bioscience

Alternative Names: ProINS-Tf

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Ventria Bioscience
  • Developer University of North Carolina; Ventria Bioscience
  • Class Recombinant fusion proteins
  • Mechanism of Action Ornithine decarboxylase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Diabetes mellitus

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Diabetes-mellitus in USA
  • 12 Feb 2013 Early research in Diabetes mellitus in USA (unspecified route)
  • 12 Feb 2013 Ventria Bioscience and the University of Southern California receive SBIR grant from the US National Institutes of Health for proinsulin-transferrin fusion protein development in Diabetes mellitus
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top